Removal of the 5′ cap on mRNA by the decapping enzyme Dcp2 is a critical step in 5′-to-3′ mRNA decay. Understanding the structural basis of Dcp2 activity has been a challenge because Dcp2 is dynamic and has weak affinity for the cap substrate. Here we present a 2.6-Å-resolution crystal structure of a heterotrimer of fission yeast Dcp2, its essential activator Dcp1, and the human NMD cofactor PNRC2, in complex with a tight-binding cap analog. Cap binding is accompanied by a conformational change in Dcp2, thereby forming a composite nucleotide-binding site comprising conserved residues in the catalytic and regulatory domains. Kinetic analysis of PNRC2 revealed that a conserved short linear motif enhances both substrate affinity and the catalytic step of decapping. These findings explain why Dcp2 requires a conformational change for efficient catalysis and reveals that coactivators promote RNA binding and the catalytic step of decapping, possibly through different conformational states.
a r t i c l e s All eukaryotic mRNA transcripts carry a 5′-end 7-methylguanosine (m 7 G) cap that is critical for splicing, export, translation, and mRNA stability 1, 2 . Removal of the 5′ cap inhibits translation initiation and generally commits an mRNA transcript to rapid degradation via 5′-to-3′ mRNA-decay pathways 3 . Cap cleavage is carried out by the conserved decapping enzyme Dcp2, a Nudix hydrolase family member that catalyzes the hydrolysis of the m 7 GpppN cap structure and releases m 7 GDP and 5′-monophosphate RNA [4] [5] [6] . Decapped monophosphate RNA transcripts are then targeted and fully degraded by conserved 5′-to-3′ exonucleases 7 . Decapping plays an important role in a variety of cellular pathways including bulk 5′-to-3′ mRNA decay 4, 5 , decay of long noncoding RNAs 8 , microRNA-mediated decay 9,10 , nonsense-mediated decay [11] [12] [13] , Staufen-mediated decay 14, 15 , transcription termination 16 , and decay of transcripts containing nonoptimal codons 17 . Recent studies in mammalian cells have linked Dcp2 function to diseases related to RNA quality control, such as spinal muscular atrophy 18 , and to the innate immunity pathway and the interferon reponse 19 . Dcp2 activity is regulated by a network of protein-protein interactions with proteins including the essential activator Dcp1 (ref. 20) and general and pathway-specific coactivators such as Edc1-4 (refs. [21] [22] [23] [24] [25] [26] , PNRC1 and PNRC2 (ref. 27 ), Pat1-Lsm1-7 (refs. [28] [29] [30] , and Dhh1 (ref. 31) . Together with RNA and coactivator proteins, the Dcp1-Dcp2 complex forms the catalytic core of decapping ribonucleoprotein complexes, which play a critical role in regulating cellular mRNA stability and gene expression.
Dcp2 is a bilobed enzyme consisting of a conserved N-terminal regulatory domain that binds the activator Dcp1, a catalytic Nudix domain that binds RNA and carries out cap-hydrolysis chemistry, and a disordered C-terminal extension of variable length that contains protein-protein-interaction motifs 20, [32] [33] [34] [35] . The regulatory and catalytic domains of Dcp2 are connected by a short flexible linker, which allows Dcp2 to adopt multiple conformations in solution 36 . Although the Nudix domain can bind RNA and perform cap hydrolysis in isolation, both Dcp1 and the regulatory domain of Dcp2 are essential for decapping in yeast 3 . Moreover, Dcp1 and the regulatory domain of Dcp2 enhance catalytic activity by 10-fold and 100-fold, respectively, in vitro 37 . Biochemical and NMR data have suggested that the regulatory domain contains a binding site for the 5′ cap and that cap recognition occurs via a composite active site composed of residues in both the Nudix and regulatory domains of Dcp2 (ref. 37 ). However, very weak affinity of Dcp2 for the cap (~10 mM) 37 as well as the enzyme's conformational dynamics 36 have made characterization of the substrate-bound, catalytically active state of the enzyme challenging, and a molecular-level understanding of Dcp2 catalysis has been elusive.
Dcp1 acts as a platform for binding decapping coactivator proteins that contain conserved short linear interaction motifs, which are found in many eukaryotes including yeast, insects, and vertebrates 38 . These include the enhancer of decapping proteins (Edc1 and Edc2), human PNRC2, and probably PNRC1 (refs. 21, 22, 27) . These proteins contain a proline-rich motif that binds a hydrophobic cleft in Dcp1 and residues N-terminal to this motif, thereby enhancing RNA binding and substrate catalysis by the Dcp1-Dcp2 complex. Recently, Valkov et al. have shown that a similar activator in Schizosacharomyces pombe (denoted with the prefix Sp), Sp Edc1 (also known as Dbs1), promotes a large conformational change in the Dcp1-Dcp2 complex, in which the RNA-binding helix of the Dcp2 Nudix domain is moved close to a positively charged surface of Dcp1 and probably creates a channel that binds RNA 39 . On the basis of this new conformation of Dcp1-Dcp2, activation of the decapping complex has been proposed to occur primarily by promoting a conformation of the enzyme that enhances affinity for RNA. However, this structure, and all previous structures of Dcp2 or a r t i c l e s Dcp1-Dcp2, do not have cap substrate bound to the enzyme, so it has been unclear how the decapping complex recognizes and hydrolyzes the 5′ cap of mRNA.
We have recently described the discovery and characterization of a tight-binding two-headed cap analog that binds Dcp2 with 20-foldhigher affinity than that of the native cap or any previously tested cap analog 40, 41 . We sought to use this tight-binding cap analog as well as Edc or PNRC coactivators as tools to trap the substrate-bound, catalytically active conformation of the Dcp1-Dcp2 decapping complex. Here we show that binding of the cap analog to a PNRC2-Dcp1-Dcp2 complex induces a conformation of Dcp2 that, to our knowledge, has not been previously described, thus revealing a composite substrate-binding site composed of residues in the regulatory and Nudix domains. A conformational change brings together conserved cap-binding residues that are either buried or far apart in all other structures of Dcp2 or Dcp1-Dcp2. Furthermore, in this cap-bound structure, a positively charged tunnel extends from the RNA-binding helix of the Nudix domain to the composite cap-binding site, thus suggesting a new path for RNA binding. Finally, we show that a conserved short linear motif in PNRC and Edc1 and Edc2 coactivator proteins activates decapping at the level of substrate binding and the catalytic step. Our cap-bound structure of Dcp1-Dcp2 provides what is, to our knowledge, the first molecular-level picture of cap recognition by Dcp2, explains a wealth of prior biochemical and biophysical data, and allows the different conformational states of Dcp2 to begin to be interpreted within the broader context of the enzyme's catalytic cycle.
RESULTS

A unique conformational change in Dcp2 for cap binding
Fission yeast Dcp1-Dcp2 has been crystallized in prior studies, and we found that coactivator human (denoted by the prefix Hs) PNRC2 robustly stimulated decapping of this complex in vitro ( Supplementary Fig. 1a,b) . Accordingly, we set out to determine structures of Sp Dcp1-Dcp2 in complex with the coactivator Hs PNRC2 and in the presence of a tight-binding 'two-headed' cap analog, to trap and structurally characterize a substrate-bound, activated conformation of the decapping enzyme. For crystallization studies, we found that Hs PNRC2(91-121) was sufficient to activate fission yeast Dcp1-Dcp2 and that single-chain constructs of Hs PNRC2(91-121) covalently tethered to the N terminus of Sp Dcp2(1-243), in complex with Sp Dcp1 (hereafter denoted Dcp1-scPNRC2Dcp2), were both catalytically active and amenable to crystallization ( Supplementary Fig. 1c,d) .
To explore the role of PNRC2 in the activation of decapping, we first determined a 3.0-Å-resolution crystal structure of the Dcp1-scPN-RC2Dcp2 complex in the absence of cap analog ( Fig. 1a , Table 1 and Supplementary Fig. 2a ). Although the crystal form of this complex is different from those of other known structures of Dcp1-Dcp2, the conformation of the apo Dcp1-Dcp2 heterodimer is very similar to the previously published 'closed' , ATP-bound conformation of the enzyme 20 and is nearly identical to a recently published structure of Dcp1-Dcp2 (ref. 39) ( Supplementary Fig. 2b,c) . As we have reported previously, this conformation of the enzyme is incompatible with substrate binding and catalysis 37 . Our structure also shows residues 100-115 of Hs PNRC2 bound to the aromatic cleft of Sp Dcp1 in a conformation similar to that seen in Hs PNRC2 bound to Hs Dcp1 (ref. 27) . Although residue 100 of PNRC2 points toward the Nudix domain, the density for residues 91-99 of PNRC2 is unobservable, presumably because of disorder. This disordered region of PNRC2 contains a conserved YAGxxF motif that is shared with coactivators Edc1 and Edc2 and is critical for Dcp2 activation in yeast 22 .
To determine how the cap interacts with the decapping complex, we soaked a tight-binding two-headed cap analog into the aforementioned Dcp1-scPNRC2Dcp2 crystals and solved a 2.6-Å-resolution substrate-analog-bound structure of the heterotrimer (Fig. 1b , Table 1 and Supplementary Fig. 3 ). The two-headed cap analog consists of two m 7 G nucleotides linked by a tetraphosphate bridge, which binds 20-fold more tightly than the native cap and is readily hydrolyzed by Dcp2 when it is either a cap analog alone or incorporated at the 5′ end of RNA 40 . Binding of this cap analog induces a substantial conformational change in Dcp2 within the crystal, primarily consisting of a 25° rotation of the Nudix domain away from Dcp1, relative to the apo structure ( Fig. 1c and Supplementary Video 1) . Reorientation of the Nudix domain for cap binding is accommodated by a restructuring of the C-terminal helix of the Dcp2 regulatory domain and the flexible linker that connects the regulatory and Nudix domains, which together form an extended hinge region. A twisting motion in the extended hinge elongates the regulatory-domain C-terminal helix by a full turn and reorients the conserved residue Y92 (Fig. 1d) . In this position, Y92 points toward the interior of the protein rather than toward solvent, and it binds one of the m 7 G nucleotides of the two-headed cap analog. Extension of the C-terminal helix in the regulatory domain also shifts the conserved residue K93 from a flexible linker into a helical secondary structure, in which it is positioned for substrate binding. Finally, rotation of the Nudix domain brings conserved residues Y220 and W43 into alignment, and a rotameric change of W43 allows these two aromatic residues to bind the second m 7 G nucleotide of the two-headed cap analog ( Fig. 1e) .
Although we have not yet trapped the transition state of decapping, because the catalytic base E147 is too far from the substrate to allow chemistry to be performed, our cap-analog-bound structure of Dcp2 reveals a new conformation of the decapping enzyme that demonstrates the structural basis of cap binding and recognition. Critically, the conserved aromatic residues (W43, Y220 and Y92) that form the basis for cap binding are either occluded or separated by large distances in all other Dcp1-Dcp2 structures, including the recently published 'activated' Sp Edc1-Dcp1-Dcp2 structure 39 ( Supplementary Fig. 4 ). The new Dcp2 conformation in our cap-analog-bound Dcp1-Dcp2 complex suggests that previously identified conformations of Dcp2 are incapable of binding and hydrolyzing cap substrate and must undergo large conformational changes in order to recognize the 5′ mRNA cap.
A composite substrate-binding site recognizes the cap
The conformational change observed in Dcp2 after cap-analog binding results in a repositioning of residues at the Dcp2 interdomain interface, thereby forming a composite substrate-binding site in which catalytically important conserved residues in both the Nudix and regulatory domains of Dcp2 recognize the cap ( Fig. 2a and Supplementary Fig. 5 ). One m 7 G nucleotide of the two-headed cap analog is sandwiched by the conserved aromatic residues W43 and Y220, and D47 forms hydrogen bonds with the 7-methylguanine ring that mimic Watson-Crick base-pairing ( Fig. 2b) . This nucleotide binding mode, which is very similar to that of m 7 G-cap-recognition motifs in eIF4E and CBP20 (refs. 42,43) , explains why W43 and D47 are strongly perturbed by m 7 GDP in NMR titration experiments, why W43 is required for nucleotide-dependent compaction of Dcp2 in SAXS experiments 37 , and why these residues in the regulatory domain are critical for cap binding and catalysis (Supplementary Table 1 ). Mutation of W43 impairs the catalytic step of decapping by 20-fold, whereas mutation of D47 decreases the catalytic step by 80-fold, to nearly the same level as that reported to result from deletion of the a r t i c l e s entire regulatory domain in vitro 37 . Both W43 and D47 are critical for activation by Dcp1 and the coactivator Edc1, and their mutation results in large decapping defects in vivo 32, 36 . Y220 and K127, both of which have modest (approximately two-fold) effects on decapping 33 , make hydrogen-bond contacts with the phosphate backbone of the cap. Similarly, E39 appears to make a hydrogen-bond contact with the 2′-OH of the ribose ring, and its mutation has an approximately two-fold effect on decapping 32 .
The second m 7 G nucleotide of the cap analog is bound by a cluster of residues located in the extended hinge region between the regulatory and catalytic domains of Dcp2 (Fig. 2c) . The conserved residue Y92 stacks against the 7-methylguanine base and hydrogen-bonds with the phosphate chain of the cap analog. Mutation of Y92 results in an approximately five-fold defect in decapping in vivo 32 . Interestingly, in NMR titration experiments with the isolated Dcp2 regulatory domain have indicated that Y92 resonances are not perturbed by the addition of m 7 GDP or two-headed cap analog 37, 40 , thus suggesting that conformational changes in the hinge region and its coupling with Nudix-domain motions are critical for cap recognition. After cap binding, the conserved residue K93 moves from a flexible linker to a structured helix and probably makes multiple hydrogen-bond contacts with the phosphate chain of the cap; its mutation results in modest decapping defects both in vitro and in vivo 32, 33 . Finally, D88 makes hydrogen-bond contacts with the 7-methylguanine base of the cap analog that mimic Watson-Crick base pairing. In summary, the cap is bound by a composite nucleotide-binding site primarily consisting of conserved residues in both the regulatory and Nudix domains, and in the extended hinge region between the two domains of Dcp2. The existence of a composite cap-binding site, as predicted by solution NMR and kinetic analyses, explains the nearly 100-fold a r t i c l e s enhancement of catalysis contributed by the regulatory domain of Dcp2 in vitro as well as the catalytic importance of many conserved residues at the Dcp2 interdomain interface 37 .
Cap-analog binding reveals possible RNA-binding tunnel
The rotation of the Dcp2 Nudix domain that composes the composite cap-binding site also creates a positively charged tunnel that leads from the dorsal helix of the Nudix domain, through a cavity between the regulatory and catalytic domains of Dcp2, directly to the capbinding site (Fig. 3) . The dorsal helix contains the positively charged Box B motif, whose conserved lysine or arginine residues are critical for RNA binding 20, 35 . The flexible lysine-rich loop on the dorsal surface of the catalytic domain (K208-K216) has also been shown to be important for RNA binding 33 , and several lysine residues in this loop (K208 and K209) sit just below the entrance to the positively charged tunnel. Strikingly, the cap-bound conformation of Dcp2 shifts K216 from a flexible solvent-exposed loop to a more structured helical turn that points the side chain of K216 directly into the positively charged tunnel (Fig. 3a) . This observation raises the intriguing possibility that the RNA body might bind the dorsal surface of the Nudix domain and then thread through a composite tunnel between the regulatory and Nudix domains, thereby accessing the cap-binding site. If RNA does thread through the positively charged tunnel, the nucleotide of the two-headed cap analog bound by W43, Y220 and D47 represents the first transcribed nucleotide of RNA, and the nucleotide bound by Y92 is the m 7 G of the cap. Several lines of evidence support this hypothesis. First, W43 and D47 have been found to bind both m 7 GDP and GDP in NMR titrations with the regulatory domain 37 . Second, in a previous structure of Dcp1-Dcp2, Y220 binds the adenine base of ATP 20 . Third, several other Nudix enzymes, including Ap 4 A hydrolase and MTH1, use a conserved aromatic residue at the Y220 position to bind substrate nucleotides 44, 45 . These observations, together with our structure, suggest that the W43-D47-Y220 composite nucleotide-binding site may bind the first transcribed nucleotide of mRNA and that the RNA body may thread through the positively charged tunnel to the RNA-binding residues located on the dorsal surface of the Dcp2 Nudix domain. However, we cannot rule out the possibility that RNA takes an external route around the side of the Nudix domain and that the m 7 G of the cap is bound by W43, Y220 and D47 near the center of the complex (Supplementary Fig.  6 ). Distinguishing these RNA binding modes will require an RNAbound structure of Dcp2.
A conserved activation motif enhances substrate binding and catalysis
Coactivators such as PNRC2, Edc1 and Edc2 share two conserved short linear motifs: a C-terminal proline-rich Dcp1-binding motif and a YAGxxF Dcp2 activating motif located 8-10 amino acids N-terminal to the Dcp1-binding motif (Fig. 4a ) that in Sc Edc1 is required for activation of Dcp2 (ref. 22) . Sequence alignment reveals that Sp Edc1 (or Dbs1) also contains the tandem Dcp2-activating and Dcp1-binding sequences in a predicted disordered region of the protein, and we found a r t i c l e s that this protein robustly activates decapping (Supplementary Fig.  7a ). Valkov et al. have recently shown that Sp Edc1 peptides containing both motifs also promote a new conformation of the Dcp1-Dcp2 decapping complex, in which the YAGxxF motif extends a β-sheet in the Nudix domain of Dcp2, thereby stabilizing a conformation of the enzyme that may enhance RNA binding 39 .
In our Dcp1-scPNRC2Dcp2 structures, the N terminus of the PNRC2 peptide, which contains the YAGxxF activation motif, was disordered and could not be modeled. Because our structure had no apparent density for the Dcp2-activation motif, we used kinetic analysis to understand how this motif might stimulate Dcp2. We coexpressed and purified complexes of Hs PNRC2(1-121) Figure 3 The cap-bound conformation of Dcp2 includes a positively charged tunnel that may bind RNA. (a) Electrostatic surface potential of the cap-bound conformation of Dcp1-Dcp2 (−7 to +7 kT/e; PNRC2 is not shown). The location of RNA-binding residues are labeled in white, and an orange arrow shows a possible path for RNA binding through the tunnel to the cap-binding site. The inset shows a close-up view of the positively charged tunnel and the movement of K216 from a solvent-exposed flexible loop in the apo structure (gray) to a more structured conformation that points into the putative RNA-binding tunnel in the cap-bound structure (green sticks). (b) Cartoon views of the cap-bound Dcp1-Dcp2 structure oriented as in a. Dcp1 is yellow, the Dcp2 regulatory domain is purple, the Dcp2 Nudix domain is green, residues important for RNA binding are highlighted as blue sticks, and the catalytic base E147 is shown in red. a r t i c l e s in which each of the four conserved residues in the Dcp2-activating motif were individually mutated to alanine (or glycine in the case of A94), and we determined the K m and k max for decapping of a 355-mer RNA substrate in vitro under single-turnover conditions 46 (Fig. 4b,c,  Supplementary Fig. 7b,c and Supplementary Data Set 1) . Addition of wild-type Hs PNRC2(1-121) to Sp Dcp1-Dcp2 robustly activated decapping, increasing k max by 12-fold and decreasing K m by seven-fold, thus suggesting that PNRC2 enhances both the catalytic step and substrate binding. A single point mutation in the activation motif, Y93A, completely abolished any activation of k max by PNRC2 while leaving the K m unchanged. Point mutants A94G and F98A had an intermediate effect on PNRC2-mediated activation, producing only a four-fold stimulation of k max compared with that of Dcp1-Dcp2 alone. The G95A mutation had no effect on k max . For all of the single point mutations in the Dcp2-activating motif, the K m remained unchanged, and PNRC2 retained its ability to lower the K m of Dcp1-Dcp2. These results are consistent with those from previous studies of the coactivator Sc Edc1, which have shown that residues N-terminal to the YAGxxF motif are primarily responsible for changes in K m , whereas peptides containing both the Dcp2-activating and Dcp1-binding motifs are sufficient to fully stimulate k max 22 . Our kinetic analysis suggests that coactivators containing the conserved Dcp2-activating and Dcp1-binding motifs stimulate decapping by enhancing both the catalytic step (increasing k max ) and substrate affinity (decreasing K m ), and that mutations in the conserved activation motif affect only PNRC2-mediated activation of the catalytic step.
DISCUSSION
Over the past decade, the decapping enzyme Dcp2 has been crystallized in a number of very different conformations and extensively characterized biochemically. However, a major obstacle to understanding how different conformational states affect catalysis has been its weak affinity for 5′-cap substrate and the consequent lack of a substrate-bound Dcp2 structure. We crystallized a complex of Hs PNRC2 and Sp Dcp1-Dcp2 (Dcp1-scPNRC2Dcp2) bound to a synthetic two-headed cap analog, which demonstrates how Dcp2 engages the cap substrate ( Fig. 1) . Our structure reveals a new conformation of the enzyme that reorganizes catalytically critical conserved residues a r t i c l e s at the interface of the regulatory and Nudix domains of Dcp2 and consequently forms a composite nucleotide-binding site (Fig. 2) . This portrait is consistent with results of previous studies showing that both the regulatory and Nudix domains of Dcp2 bind the 5′ cap and that cap recognition occurs during the catalytic step of decapping 37 . Our cap-bound structure provides a rationale for why the regulatory domain contributes 100-fold to the k max in vitro and why the conserved residues D47 and W43 are critical for cap binding and contribute 80-fold and 20-fold to the k max , respectively. The role of W43 in cap recognition is also consistent with its importance in the nucleotide-dependent compaction of the Dcp1-Dcp2 complex observed in SAXS experiments 37 . Furthermore, we identified additional conserved residues that make contacts with the cap, such as Y92, K93, Y220, and E39, thus explaining why mutation of these residues results in in vitro and/or in vivo decapping defects 32, 33, 37 coactivator Sp Edc1 appears to promote this conformation by bridging an extended surface of the Nudix and regulatory domains of Dcp2. From this structure and data showing that Edc1 and the positively charged surface of Dcp1 enhance RNA binding, the authors concluded that this conformation represents the active conformation of the decapping enzyme and that activation by Edc1-like coactivators and Dcp1 is primarily accomplished by improved binding of RNA substrate. However, our cap-bound conformation of Dcp1-Dcp2 suggests that the Edc1-bound conformation solved by Valkov et al. 39 is incompatible with 5′-cap recognition and therefore incompatible with catalysis. Residues that compose the composite nucleotide-binding site in our structure are either buried or separated by large distances in the Edc1-Dcp1-Dcp2 structure (Supplementary Fig. 4c ). For example, in the Edc1-bound structure, D47 and W43, which are critical for cap binding and catalysis, are buried in the protein-protein interface between the regulatory domain and Edc1, and are thus unavailable for cap binding. Likewise, W43 and Y220, residues in the regulatory and Nudix domains of Dcp2 that come together in our structure and bind one nucleotide of the cap are separated by nearly 20 Å in the Edc1-bound conformation.
The apparent conflict between the cap-bound conformation of Dcp2 identified in this study and the Edc1-bound conformation of Dcp2 identified by Valkov et al. 39 may be reconciled by our kinetic analysis of the conserved Dcp2-activating YAGxxF motif found in PNRC2 and Edc1 coactivators (Fig. 4) . In agreement with previous kinetic data on Sc Edc1, our data indicated that Hs PNRC2 activates decapping catalysis by both enhancing substrate binding (approximately ten-fold decrease in K m ) and accelerating the catalytic step (~12-fold increase in k max ). These results raise the possibility that the different conformational states of Dcp2 may reflect different steps in the enzyme's catalytic cycle, and that Edc1-like coactivators may promote these different steps (Fig. 5) . Indeed, it has previously been shown that conformational dynamics is crucial for Dcp2 catalysis and activation of catalysis by Sc Edc1, and the dynamics critically depends on the 'gatekeeper' residue W43 (ref. 36) , which plays very different roles in the cap-bound versus Edc1-bound structures. The Edc1bound conformation characterized by Valkov et al. 39 may represent an early step in the catalytic cycle, in which Edc1 binding promotes a conformation of the decapping complex primed for RNA binding, and possibly scanning along the RNA body, thus accounting for Edc1's ability to enhance RNA binding. In a subsequent step, recognition of the RNA 5′-cap target may result in a large conformational change in Dcp2, thus generating the composite nucleotide-binding site identified in our cap-analog-bound structure. Finally, a further conformational change in Dcp2 would be required to access the transition state to decapping. Edc1-like coactivators would also act during this step, possibly by contacting the Nudix domain or the cap itself, because the primary role of the conserved YAGxxF Dcp2-activating motif is to promote the catalytic step, not substrate binding.
This model for RNA recognition by Dcp1-Dcp2 has precedents in other nucleic acid-binding proteins, such as transcription factors, restriction enzymes, or DNA-repair enzymes, which use scanning or facilitated diffusion to quickly scan long stretches of DNA for target sequences 47, 48 . Many of these proteins, such as the lac repressor, use one conformation to carry out nonspecific DNA binding during scanning and switch to a different conformation after specific target recognition 49 . Although further experiments will be required to test these possibilities for the decapping complex, regulation of mRNA decapping may be controlled by protein-protein interactions that manipulate the conformational transitions of Dcp2 and consequently promote or inhibit different steps in the catalytic cycle. The cap-analog-bound structure of Dcp2 presented here defines the structural basis of cap recognition and lays a groundwork for understanding how different conformational states of Dcp2 might be leveraged by the cell to control decapping and mRNA stability.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. Coordinates and structure factors have been deposited in the Protein Data Bank under accession codes PDB 5KQ1 (Dcp1-scPNRC2Dcp2 complex) and PDB 5KQ4 (Dcp1-scP-NRC2Dcp2 complex with bound two-headed cap analog).
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
